ABUSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Arbutus Biopharma Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$4.23+0.01 (+0.24%)
Close on Oct 19, 2026
- Market cap
- $835.30M
- P/E (TTM)
- 5.4
- Dividend yield
- –
Arbutus Biopharma statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Arbutus Biopharma | Industry median |
|---|---|---|
| Market Cap | $836.90M | $166.30M |
| Enterprise Value | $744.27M | $88.19M |
| PE Ratio | 5.42 | 20.44 |
| PS Ratio | 4.61 | 3.65 |
| PB Ratio | 3.23 | 2.03 |
| P/TBV Ratio | 3.23 | 2.29 |
Enterprise value
| Measure | Arbutus Biopharma | Industry median |
|---|---|---|
| EV / Sales | 4.10 | 2.51 |
| EV / EBITDA | 5.00 | 14.65 |
| EV / EBIT | 5.00 | 19.00 |
Income (trailing twelve months)
| Measure | Arbutus Biopharma | Industry median |
|---|---|---|
| Revenue | $181.72M | $58.34M |
| Operating Income | $149.00M | -$21.40M |
| Net Income | $153.05M | -$22.46M |
| EBITDA | $149.00M | -$16.91M |
| EPS (Diluted) | $0.78 | -$0.83 |
Margins
| Measure | Arbutus Biopharma | Industry median |
|---|---|---|
| Operating Margin | 82.0% | -44.0% |
| Profit Margin | 84.2% | -40.2% |
| EBITDA Margin | 82.0% | -30.2% |
Returns
| Measure | Arbutus Biopharma | Industry median |
|---|---|---|
| Return on Equity (ROE) | 89.6% | -53.2% |
| Return on Assets (ROA) | 81.1% | -40.9% |
| Return on Invested Capital (ROIC) | 155.9% | -32.4% |
| Return on Capital Employed (ROCE) | 55.0% | -38.1% |
Growth
| Measure | Arbutus Biopharma | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 1078.8% | 5.96% |
| Revenue Growth (3Y CAGR) | -28.8% | 2.25% |
| Revenue Growth (5Y CAGR) | 15.3% | 6.48% |
Balance sheet
| Measure | Arbutus Biopharma | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $92.63M | $61.43M |
| Net Cash (Debt) | $92.63M | $15.35M |
| Net Cash Per Share | $0.47 | $0.66 |
| Equity (Book Value) | $258.73M | $49.09M |
| Book Value Per Share | $1.31 | $1.37 |
| Tangible Book Value | $258.73M | $23.52M |
| Working Capital | $270.52M | $76.81M |
Financial position
| Measure | Arbutus Biopharma | Industry median |
|---|---|---|
| Current Ratio | 81.42 | 3.34 |
| Quick Ratio | 27.64 | 2.44 |
| Interest Coverage | 1960.46 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Arbutus Biopharma | Industry median |
|---|---|---|
| Operating Cash Flow | -$24.63M | -$12.35M |
Efficiency
| Measure | Arbutus Biopharma | Industry median |
|---|---|---|
| Asset Turnover | 0.96 | 0.39 |
| Revenue Per Employee | $9.56M | $404.87K |
| Profits Per Employee | $8.06M | -$703.34K |
| Employee Count | 19 | 74 |
Dividends and yields
| Measure | Arbutus Biopharma | Industry median |
|---|---|---|
| Earnings Yield | 18.3% | -23.3% |
Shares
| Measure | Arbutus Biopharma | Industry median |
|---|---|---|
| Shares Outstanding | 197,848,000 | 58,127,000 |
| Shares Change (YoY) | 1.97% | 10.9% |
| Shares Change (QoQ) | 0.35% | 0.54% |
| Float | 126,211,000 | 49,136,700 |
| Shares Held by Insiders | 36.2% | 11.6% |
| Shares Held by Institutions | 71.1% | 59.4% |
Scores
| Measure | Arbutus Biopharma | Industry median |
|---|---|---|
| Graham Number | $4.79 | $18.73 |
| Graham Upside | 13.3% | -45.1% |
| Altman Z-Score | 30.27 | -0.22 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Arbutus Biopharma's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.